... records reveal psych disorders, thryomegaly, menorrhagia ... patient started quetiapine treatment on 10 ... M ADD, ODD (oppositional defiance disorder) psychotic disorder ...
Center for Biologics Evaluation and Research (CBER)
... In addition, aripiprazole is approved for short-term use (6 weeks) as adjunctive treatment with lithium or valproate in this population. ...
Center for Drug Evaluation (CDER)
... Abilify Expert Opinion Drug Metabolism and Toxicology Article. ... Expert Opinion Drug Metabolism and Toxicology, 7(5):591-608. -. -. Links on this page: ...
... Pub. L. 108�155), for Fluarix (influenza virus vaccine), Afluria (influenza virus vaccine), and Abilify (aripiprazole). There ...
... a. A single-dose fasting in-vivo bioequivalence study comparing Aripiprazole Tablets, 10 mg, to the reference listed drug (RLD), Abilify � , ...
We aimed to review and synthesize results reporting on the maintenance efficacy of Aripiprazole in adults with bipolar I disorder. Aripiprazole is FDA approved for the acute and maintenance treatment of bipolar I disorder. Aripiprazole�s efficacy during the long-term treatment of bipolar disorder is supported by extension of acute ...
PubMed Central
RationaleAripiprazole (Abilify) is an atypical antipsychotic drug characterized by partial agonist activity at dopamine (DA) D2/D3 receptors and a low side-effect profile. While we previously demonstrated that acute aripiprazole blocked the reinstatement of cocaine seeking in an animal ...
We aimed to review and synthesize results reporting on the maintenance efficacy of Aripiprazole in adults with bipolar I disorder. Aripiprazole is FDA approved for the acute and maintenance treatment of bipolar I disorder. Aripiprazole's efficacy during the long-term treatment of bipolar disorder is supported by extension of acute ...
PubMed
Aripiprazole was recently US FDA-approved to treat irritability in children and adolescents with autistic disorder aged 6�17 years. There are currently only two psychotropics approved by the FDA to treat irritability in the autistic population. This drug profile will discuss available studies of aripiprazole in individuals with pervasive developmental ...
Objective:To review published literature regarding aripiprazole in child and adolescent psychiatry.Method:A literature review was conducted using the MEDLine search term: �aripiprazole� with limits: Human trials, English language, All Child (aged 0�18 years). Additional articles were identified from reference information and poster presentation ...
ObjectiveTo evaluate the cost-effectiveness of aripiprazole and olanzapine in patients with schizophrenia.MethodsData from a double-blind, randomized study demonstrating the efficacy of aripiprazole and olanzapine were used to observe new incidence of metabolic syndrome (26-week therapy) and to model the risk of developing diabetes ...
Kasteng F, Eriksson J, Sennf�lt K, Lindgren P. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Objective:? To assess the cost-effectiveness of aripiprazole versus olanzapine in the treatment of patients with schizophrenia or bipolar disorder in Sweden with focus on the ...
Psychosis of Alzheimer�s disease (AD) is characterized by delusions or hallucinations and may be associated with agitation, negative symptoms or depression. There are no psychotropic medications that are approved by the US FDA for the treatment of psychosis of AD. However, atypical antipsychotics have been widely used and recommended by geriatric experts in the management of psychosis of AD in ...
Page 1. Contains Nonbinding Recommendations Draft Guidance on Aripiprazole This draft guidance, once finalized, will represent the ...
PURPOSE: To investigate the effects of coadministration of paroxetine or fluvoxamine on the pharmacokinetics of aripiprazole in healthy adult Japanese with different CYP2D6 genotypes. METHODS: Fourteen CYP2D6 extensive metabolizer (EM) and 14 CYP2D6 intermediate metabolizer (IM) subjects were coadministered a single oral dose of ...
... impulsive behavior � having more energy and restlessness than usual ... loss of interest in activities that you once enjoyed and loss of energy ...
Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Major Depressive Disorder; Anxiety Disorders; Substance Abuse
ClinicalTrials.gov
... Weight gain + hepatic steatosis � Reproductive system and breast disorders (1): Priapism � Injury, poisoning and procedural complications (1): Heat ...
Epidemiological and experimental data indicate that maternal undernutrition may sensitize the offspring to the apparition of chronic diseases such as metabolic syndrome and schizophrenia, suggesting that these pathologies may have a developmental origin. To test this hypothesis, we have compared the effects of a 4weeks treatment of clozapine (30mg/kg once daily, p.o.) or ...
For patients who gain a troublesome amount of weight on antipsychotics, switching to a less obesogenic agent is an option. Aripiprazole appears to cause less weight gain than many other antipsychotics. We report on changes in weight, and other risk factors for heart disease, in thirty-three schizophrenia patients who agreed to switch from other antipsychotics to ...
INTRODUCTION: The search for drugs that reduce psychotic symptoms, with minimal adverse effects, has led to the development of new agents that act somewhat differently from their older antipsychotic counterparts. These agents, which include aripiprazole, lurasidone and perospirone, act by targeting both D? and 5-HT(1A) receptors, in addition to other characteristic receptors. ...
Although clozapine proved effective in treating 30-50% of the cases of resistant schizophrenia, its clinical use is hampered by significant side effects. To overcome this problem, augmentation with other atypical antipsychotics has been attempted, with conflicting results. A clozapine-aripiprazole combination showed interesting properties, due to the favourable complementary ...
Background: With increasing use of atypical antipsychotics among pediatric patients, detailed information about safety and tolerability is crucial.Method: Data were pooled from two 8-week, randomized, double-blind, multicenter, parallel-group trials comparing aripiprazole versus placebo in subjects aged 6 to 17 years with irritability associated with DSM-IV-TR-diagnosed ...
Background: With increasing use of atypical antipsychotics among pediatric patients, detailed information about safety and tolerability is crucial.Method: Data were pooled from two 8-week, randomized, double-blind, multicenter, parallel-group trials comparing aripiprazole versus placebo in subjects aged 6 to 17 years with irritability associated with DSM-IV-TR�diagnosed ...
Clozapine is associated with significant weight gain and metabolic disturbances. This multicentre, randomized study comprised a double-blind, placebo-controlled treatment phase of 16 wk, and an open-label extension phase of 12 wk. Outpatients who met DSM-IV-TR criteria for schizophrenia, who were not optimally controlled while on stable dosage of clozapine for > or =3 ...
Delusions, hallucinations and other psychotic symptoms can accompany a number of conditions in late life. As such, elderly patients are commonly prescribed antipsychotic medications for the treatment of psychosis in both acute and chronic conditions. Those conditions include schizophrenia, bipolar disorder, depression and dementia. Elderly patients are at an increased risk of adverse events from ...
Objective: The authors conducted a multisite randomized controlled trial examining the strategy of switching from olanzapine, quetiapine, or risperidone to aripiprazole to ameliorate metabolic risk factors for cardiovascular disease. Method: Patients with schizophrenia or schizoaffective disorder with a body mass index ?27 and non-high-density lipoprotein ...
Although there are well-established psychiatric procedures available concerning switching of antipsychotic drugs, in practice we often face a situation where we have to consider not only the patient's demands, but also requests from relatives. In this article we describe a case where we encountered this situation. Our patient was a 48-year-old married man suffering from paranoid schizophrenia with ...
By converting changes in intracellular energy status to changes in cell membrane polarization, ATP-sensitive K(+) (K(ATP)) channels in hypothalamic appetite-regulating neurons play a critical role in linking neuronal electrochemical function, metabolic and energy status, and feeding behavior. Most atypical antipsychotics (AAPs) increase the appetite of patients with ...
US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and ... 18 3.1.5.2.3 Time to Relapse by Type of Mood Episode ...
... routine and special laboratory tests (including CPK and homeostasis model assessment 42 Reference ID: 2896405 Page 43. (b) (6) ...
